CN119585286A - 吡啶并[4,3-d]嘧啶化合物 - Google Patents

吡啶并[4,3-d]嘧啶化合物 Download PDF

Info

Publication number
CN119585286A
CN119585286A CN202380051793.7A CN202380051793A CN119585286A CN 119585286 A CN119585286 A CN 119585286A CN 202380051793 A CN202380051793 A CN 202380051793A CN 119585286 A CN119585286 A CN 119585286A
Authority
CN
China
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound
mmol
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380051793.7A
Other languages
English (en)
Chinese (zh)
Inventor
J·C·德弗莱斯特
永田麻子
S·P·普兰肯
J·E·斯潘格勒尔
S·C·萨顿
J·H·塔特洛克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp SRL
Original Assignee
Pfizer Corp SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp SRL filed Critical Pfizer Corp SRL
Publication of CN119585286A publication Critical patent/CN119585286A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202380051793.7A 2022-07-05 2023-06-30 吡啶并[4,3-d]嘧啶化合物 Pending CN119585286A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202263358324P 2022-07-05 2022-07-05
US63/358,324 2022-07-05
US202263394338P 2022-08-02 2022-08-02
US63/394,338 2022-08-02
US202263414939P 2022-10-11 2022-10-11
US63/414,939 2022-10-11
US202363502931P 2023-05-18 2023-05-18
US63/502,931 2023-05-18
PCT/IB2023/056844 WO2024009191A1 (en) 2022-07-05 2023-06-30 Pyrido[4,3-d]pyrimidine compounds

Publications (1)

Publication Number Publication Date
CN119585286A true CN119585286A (zh) 2025-03-07

Family

ID=87426656

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380051793.7A Pending CN119585286A (zh) 2022-07-05 2023-06-30 吡啶并[4,3-d]嘧啶化合物

Country Status (16)

Country Link
EP (1) EP4551296A1 (enExample)
JP (1) JP2025525406A (enExample)
KR (1) KR20250029954A (enExample)
CN (1) CN119585286A (enExample)
AU (1) AU2023302139A1 (enExample)
CA (1) CA3261000A1 (enExample)
CL (1) CL2024003699A1 (enExample)
CO (1) CO2024016875A2 (enExample)
CR (1) CR20240556A (enExample)
DO (1) DOP2024000275A (enExample)
IL (1) IL317957A (enExample)
MA (1) MA71388A (enExample)
MX (1) MX2024015001A (enExample)
PE (1) PE20250259A1 (enExample)
TW (2) TW202513571A (enExample)
WO (1) WO2024009191A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119874616A (zh) * 2025-03-28 2025-04-25 四川美域高生物医药科技有限公司 一种新型有机中间体及其制备方法和应用

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3158793A1 (en) 2019-10-28 2021-05-06 Merck Sharp & Dohme Corp. Small molecule inhibitors of kras g12c mutant
US12479834B2 (en) 2019-11-29 2025-11-25 Taiho Pharmaceutical Co., Ltd. Phenol compound or salt thereof
CN118302162A (zh) * 2021-11-24 2024-07-05 默沙东有限责任公司 Kras突变蛋白的小分子抑制剂
AU2023231139A1 (en) 2022-03-11 2024-09-05 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
CN119731180A (zh) 2022-08-05 2025-03-28 金橘生物科技公司 杂环化合物及其用途
TW202434606A (zh) * 2022-11-17 2024-09-01 大陸商江蘇恆瑞醫藥股份有限公司 稠合三環類化合物、其製備方法及其在醫藥上的應用
EP4655073A2 (en) 2023-01-26 2025-12-03 Arvinas Operations, Inc. Cereblon-based kras degrading protacs ans uses related thereto
WO2024178304A1 (en) * 2023-02-24 2024-08-29 Alterome Therapeutics, Inc. Kras modulators
KR20250164828A (ko) 2023-03-30 2025-11-25 레볼루션 메디슨즈, 인크. Ras gtp 가수분해 유도를 위한 조성물 및 이의 용도
AU2024253142A1 (en) * 2023-04-05 2025-10-16 Pfizer Inc. Pyrido[4,3-d]pyrimidine compounds
WO2024218686A1 (en) * 2023-04-20 2024-10-24 Pfizer Inc. Pyrido[4,3-d]pyrimidine compounds
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
CN121194980A (zh) * 2023-05-16 2025-12-23 和记黄埔医药（上海）有限公司 三环类化合物及其用途
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
WO2025054530A1 (en) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025085748A1 (en) 2023-10-20 2025-04-24 Merck Sharp & Dohme Llc Small molecule inhibitors of kras proteins
WO2025130912A1 (zh) * 2023-12-19 2025-06-26 正大天晴药业集团股份有限公司 三并环类化合物及其医药用途
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
ES2425269T3 (es) 2007-12-14 2013-10-14 Bristol-Myers Squibb Company Moléculas de unión al receptor OX40 humano
SA112330278B1 (ar) 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
RU2638552C2 (ru) 2011-09-27 2017-12-14 Ф. Хоффманн-Ля Рош Аг Пиразол-4-ил-гетероциклил-карбоксамидные соединения и способы применения
SA112330989B1 (ar) 2011-11-17 2015-07-07 فايزر انك ببتيدات سامة للخلايا ومواد اقتران جسم مضاد وعقار منها
EP3164417A1 (en) 2014-07-01 2017-05-10 Pfizer Inc. Bispecific heterodimeric diabodies and uses thereof
TWI703159B (zh) 2015-04-13 2020-09-01 美商輝瑞股份有限公司 Bcma特異性治療性抗體及其用途
CN109563081A (zh) 2016-04-07 2019-04-02 葛兰素史克知识产权开发有限公司 可用作蛋白调节剂的杂环酰胺类
SI3440076T1 (sl) 2016-04-07 2022-09-30 Glaxosmithkline Intellectual Property Development Limited Heterociklični amidi uporabni kot proteinski modulatorji
KR102356241B1 (ko) 2016-11-16 2022-01-28 윙크 로보틱스, 인코포레이티드 미용 로보틱스용 변형 가능한 엔드 이펙터
TW201906848A (zh) * 2017-05-11 2019-02-16 瑞典商阿斯特捷利康公司 化學化合物
EP3630835A1 (en) 2017-05-31 2020-04-08 STCube & Co., Inc. Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
CN118772278A (zh) 2017-06-02 2024-10-15 辉瑞公司 Flt3的特异性抗体及其用途
US11285131B2 (en) 2017-08-04 2022-03-29 Merck Sharp & Dohme Corp. Benzo[b]thiophene STING agonists for cancer treatment
KR20220012255A (ko) * 2019-04-28 2022-02-03 젠플리트 테라퓨틱스 (상하이) 아이엔씨. 옥사아자퀴나졸린-7(8h)-케톤 화합물, 이의 제조 방법 및 이의 약학적 응용
WO2021041671A1 (en) 2019-08-29 2021-03-04 Mirati Therapeutics, Inc. Kras g12d inhibitors
CN113980032B (zh) * 2020-07-27 2023-06-16 江苏恒瑞医药股份有限公司 稠合四环类衍生物、其制备方法及其在医药上的应用
EP4262807A4 (en) * 2020-12-15 2025-04-23 Mirati Therapeutics, Inc. Azachinazoline pan-KRAS inhibitors
CN117083281A (zh) * 2021-03-24 2023-11-17 南京明德新药研发有限公司 嘧啶并杂环类化合物及其应用
TW202315626A (zh) * 2021-08-31 2023-04-16 大陸商勁方醫藥科技(上海)有限公司 嘧啶并環類化合物及其製法和用途
CN118019746A (zh) * 2021-09-27 2024-05-10 北京加科思新药研发有限公司 多环稠环衍生物及其用途

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119874616A (zh) * 2025-03-28 2025-04-25 四川美域高生物医药科技有限公司 一种新型有机中间体及其制备方法和应用

Also Published As

Publication number Publication date
WO2024009191A1 (en) 2024-01-11
CR20240556A (es) 2025-01-29
CL2024003699A1 (es) 2025-04-11
JP2025525406A (ja) 2025-08-05
TWI869913B (zh) 2025-01-11
DOP2024000275A (es) 2025-01-31
IL317957A (en) 2025-02-01
KR20250029954A (ko) 2025-03-05
MX2024015001A (es) 2025-01-09
CA3261000A1 (en) 2024-01-11
PE20250259A1 (es) 2025-01-29
TW202513571A (zh) 2025-04-01
MA71388A (fr) 2025-04-30
CO2024016875A2 (es) 2024-12-19
EP4551296A1 (en) 2025-05-14
AU2023302139A1 (en) 2024-12-19
TW202409047A (zh) 2024-03-01

Similar Documents

Publication Publication Date Title
TWI869913B (zh) 吡啶并[4,3-d]嘧啶化合物
WO2022237649A1 (en) Exocyclic amino quinazoline derivatives as kras inhibitors
KR20220100879A (ko) Fgfr 저해제로서의 이환식 헤테로사이클
CA3154073A1 (en) Isoindolinone and indazole compounds for the degradation of egfr
US12281127B2 (en) Pyrido[4,3-d]pyrimidine compounds
WO2023143312A1 (zh) 一种含氮杂环化合物、其制备方法及应用
WO2019166951A1 (en) Indole-2-carbonyl compounds and their use for the treatment of hepatitis b
TWI755788B (zh) 類鐸受體促效劑
JP2025114615A (ja) 治療薬としての細胞毒素のペプチドコンジュゲート
WO2024218686A1 (en) Pyrido[4,3-d]pyrimidine compounds
WO2024213979A1 (en) Pyrido[4,3-d]pyrimidine compounds
TW202313610A (zh) 作為ｆｇｆｒ抑制劑之三環雜環
TW202448452A (zh) 用於治療疾病之ｅｇｆｒ抑制劑
WO2024003773A1 (en) 2,7-naphthyridine compounds as mastl inhibitors
JP2025100453A (ja) ピリド［４，３－ｄ］ピリミジン化合物
KR20250100539A (ko) 피리도[4,3-d]피리미딘 화합물
US20240140947A1 (en) Compound for the treatment of cancer
WO2025094035A1 (en) Toll-like receptor agonists and conjugates thereof
WO2025235733A1 (en) Bis-bicycloheteroaryl macrocycles and their use
HK40072488A (en) Imidazo[4,5-c]pyridine derivatives as toll-like receptor agonists
HK40059656A (en) Pyridazinyl thiazolecarboxamide compound
HK1227874B (en) Tricyclic pi3k inhibitor compounds and methods of use
HK1185871A1 (zh) 三环pi3k抑制剂化合物和使用方法
HK1185871B (en) Tricyclic pi3k inhibitor compounds and methods of use

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40117290

Country of ref document: HK